AstraZeneca agreed to acquire exclusive global rights to Dizal Pharmaceutical’s oral EGFR exon 20 insertion drug Zegfrovy (sunvozertinib) in a deal worth up to $1.5 billion. AstraZeneca will pay $600 million upfront, with additional development and sales milestones, as it seeks to deepen its position in EGFR-mutated lung cancer. The drug is already approved in the U.S. and China for previously treated NSCLC with exon 20 insertions after platinum-based chemotherapy. Dizal recently reported Phase III Wu-Kong28 results in NEJM for first-line use, with Zegfrovy showing improved progression-free survival versus platinum-doublet chemotherapy. For Dizal, the agreement creates a faster path to global commercialization; for AstraZeneca, it adds an oral targeted option aimed at a segment where treatment choices remain limited.